This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Psoriasis: ixekizumab shows good effectiveness in real-world study

Takeaway

  • Ixekizumab is associated with clinical improvement and a low discontinuation rate in patients with moderate to severe psoriasis, according to a retrospective study.

Key results

  • Ixekizumab was associated with significant improvements in Psoriasis Area and Severity Index (PASI) score at 4, 12, and 24 weeks (P<.001 for all).
    • Improvements were also observed at the same times in the subgroup of patients with psoriatic arthritis when analysed by the Disease Activity 28 score (P<.001 for all).
  • At 24 weeks, 90% of patients had achieved ≥75% improvement in PASI score (PASI 75), whereas 72% had achieved PASI 90 and 57% had achieved PASI 100.
  • 2% of patients discontinued because of adverse events.

Study design

  • 110 patients with moderate to severe psoriasis who completed at least 24 weeks of ixekizumab treatment were included.
  • Funding: None.

Limitations

  • Retrospective study.
  • Small patient sample size.

References


YOU MAY ALSO LIKE